Nothing Special   »   [go: up one dir, main page]

Rosenmann, 2013 - Google Patents

Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

Rosenmann, 2013

Document ID
2572748835674542713
Author
Rosenmann H
Publication year
Publication venue
Current Alzheimer Research

External Links

Snippet

The drawbacks of amyloid immunotherapy, including the development of encephalitis, the lack of clinical improvement and of any effect on neurofibrillary tangles (NFTs), coupled with the central role of NFTs in dementia, may point that clearance of amyloid pathology is not …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Rosenmann Immunotherapy for targeting tau pathology in Alzheimer’s disease and tauopathies
JP7539446B2 (en) Methods for immunological targeting of pathological tau protein
US20200190173A1 (en) Immunotherapy for Clearing Pathological Tau Conformers
Castillo-Carranza et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles
Valera et al. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies
Fu et al. Amyloid-β immunotherapy for Alzheimer's disease
Winblad et al. Active immunotherapy options for Alzheimer’s disease
Panza et al. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies
Delrieu et al. Retracted:‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches
US9637552B2 (en) Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
Schroeder et al. Tau-directed immunotherapy: a promising strategy for treating Alzheimer’s disease and other tauopathies
Panza et al. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab
Braczynski et al. Vaccination strategies in tauopathies and synucleinopathies
Nitsch et al. Targeting β-amyloid pathology in Alzheimer’s disease with Aβ immunotherapy
Spencer et al. α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
KR20080089596A (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
US10266585B2 (en) Methods of treating brain injury
JP5952331B2 (en) Prevention and treatment of synucleinopathies and amyloidogenic diseases
Cuddy et al. Amino-terminal β-amyloid antibody blocks β-amyloid-mediated inhibition of the high-affinity choline transporter CHT
Marciani Rejecting the Alzheimer's disease vaccine development for the wrong reasons
Marciani Development of an effective Alzheimer’s vaccine
Oluwasanmi Adeloye et al. Amyloid-β Immunotherapy on Alzheimer disease: Prevention and Therapeutic Target
CHANDRAKUMARAN et al. Tau immunotherapy for Alzheimer’s
Tan et al. Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers
Liu et al. Active Immunization Against the Amyloid-β Peptide